Create a free Manufacturing.net account to continue

FDA begins process to remove breast cancer indication from Avastin label

The U.S. Food and Drug Administration announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.

FDA begins process to remove breast cancer indication from Avastin label


Visit the FDA on Facebook and Flickr
 

SOURCE

More in Operations